Morgan Stanley
JSPR icon

Morgan Stanley’s Jasper Therapeutics JSPR Stock Holding History

Morgan Stanley’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Sell
1,333,420
-636,365
-32% -$883K ﹤0.01% 5056
2025
Q4 		$3.6M Buy
1,969,785
+1,179,825
+149% +$2.37M ﹤0.01% 4419
2025
Q3 		$1.88M Buy
789,960
+20,210
+3% +$61.3K ﹤0.01% 4828
2025
Q2 		$4.27M Buy
769,750
+115,766
+18% +$570K ﹤0.01% 4183
2025
Q1 		$2.81M Buy
653,984
+49,192
+8% +$327K ﹤0.01% 4383
2024
Q4 		$12.9M Buy
604,792
+39,070
+7% +$813K ﹤0.01% 3170
2024
Q3 		$10.6M Buy
565,722
+256,303
+83% +$5.1M ﹤0.01% 3384
2024
Q2 		$7.02M Buy
309,419
+133,002
+75% +$3.19M ﹤0.01% 3610
2024
Q1 		$5.18M Sell
176,417
-163,493
-48% -$2.9M ﹤0.01% 3886
2023
Q4 		$2.68M Buy
339,910
+261,822
+335% +$1.76M ﹤0.01% 4767
2023
Q3 		$547K Buy
78,088
+45,933
+143% +$561K ﹤0.01% 5128
2023
Q2 		$441K Sell
32,155
-5,652
-15% -$84K ﹤0.01% 5283
2023
Q1 		$684K Buy
37,807
+37,502
+12,296% +$693K ﹤0.01% 5074
2022
Q4 		$1.47K Sell
305
-8
-3% -$54 ﹤0.01% 7416
2022
Q3 		$2K Buy
313
+13
+4% +$238 ﹤0.01% 7473
2022
Q2 		$6K Sell
300
-128
-30% -$3.65K ﹤0.01% 7361
2022
Q1 		$15K Sell
428
-29,451
-99% -$1.33M ﹤0.01% 7262
2021
Q4 		$2.35M Buy
29,879
+18,993
+174% +$1.78M ﹤0.01% 4455
2021
Q3 		$1.12M Buy
+10,886
New +$1.11M ﹤0.01% 4981

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley's JSPR Position: Q1 2026 in Review

Morgan Stanley reduced its Jasper Therapeutics (JSPR) stake by 32% in Q1 2026, selling an estimated $883K and leaving 1,333,420 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5056.

Morgan Stanley first reported a position in JSPR in Q3 2021 and has held it in 19 quarters since. The position peaked at $12.9M in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Morgan Stanley held 1,333,420 shares of Jasper Therapeutics worth $1.17M as of Q1 2026.
  • Morgan Stanley sold 636,365 Jasper Therapeutics shares in Q1 2026, an estimated $883K.
  • Jasper Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5056 holding.
  • Morgan Stanley first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Jasper Therapeutics position peaked at $12.9M in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.